Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: Assembly of a multiprotein signaling complex

Journal of Cellular Biochemistry

Volumn 113, Issue 5, 2012, Pages 1488-1500

  Misra, Uma K ^a   Pizzo, Salvatore V ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

4EBP1; Epac1; mTORC2; p AKTS473; PROSTATE CANCER CELLS; Rictor; S6 Kinase; SIGNALOSOME

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 (4 CHLOROPHENYLTHIO) 2' O METHYLADENOSINE 3':5' CYCLIC MONOPHOSPHATE; CYCLIC AMP DERIVATIVE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PROTEIN; PROTEIN AKAP; PROTEIN EPAC1; PROTEIN KINASE B; PROTEIN RAPTOR; PROTEIN RICTOR; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; RNA INTERFERENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARRIER PROTEINS; CELL LINE, TUMOR; CHROMONES; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; GENE SILENCING; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; MODELS, BIOLOGICAL; MORPHOLINES; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN MULTIMERIZATION; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS; THIONUCLEOTIDES; TRANSCRIPTION FACTORS; UP-REGULATION;

RAPTORES;

EID: 84859055988     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24018     Document Type: Article

References (52)

1. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes MC,. 1997. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): Structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776-789. (Pubitemid 27441832)
2. Alessi DR, Pearce LR, Garcia-Martinez JM,. 2009. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal 2: 327.
3. Andrade MA, Bork P,. 1995. HEAT repeats in the Huntington's disease protein. Nature 11: 115-116.
4. Bailey CL, Kelly P, Casey P,. 2009. Activation of Rap1 promotes prostate cancer metastasis. Cancer Res 69: 4962-4968.
5. Bellacosa A, Kumar CC, DiCristofano A, Testa JR,. 2005. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 94: 29-86. (Pubitemid 41202364)
6. Boulbes DR, Shaiken T, Sarbassov DD,. 2011. Endoplasmic reticulum is a main localization site of mTORC2. Biochim Biophys Res Commun 413: 46-52.
7. Bos JL,. 2006. Epac proteins: Multipurpose cAMP targets. Trends Biochem Sci 31: 680-686. (Pubitemid 44791945)
8. Bradford MM,. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
9. Dennis PB, Fumagalli S, Thomas G,. 1999. Target of rapamycin (TOR): Balancing the opposing forces of protein synthesis and degradation. Curr Opin Gen Dev 9: 49-54. (Pubitemid 29080386)
10. Dibble CC, Asara JM, Manning BD,. 2009. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29: 5657-5670.
11. Dodge-Kafka KL, Soughayer J, Pare GC, Michel JJC, Langeberg LK, Kapiloff MS, Scott JD,. 2005. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437: 574-578. (Pubitemid 41613557)
12. Du K, Tsichlis PN,. 2005. Regulation of the Akt kinase by interacting proteins. Oncogene 24: 7401-7409. (Pubitemid 41637980)
13. Engstrom W, Ward A, Moorwood K,. 2010. The role of scaffold proteins in JNK signalling. Cell Prolif 43: 56-66.
14. Gloerich M, Bos JL,. 2010. Epac: Defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 50: 355-375.
15. Gloerich M, Ponsioen B, Vliem MJ, Zhang Z, Kooistra MR, Price LS, Ritsma L, Zwartkruis FJ, Rehmann H, Jalink K, Bos JL,. 2010. Spatial regulation of cyclic AMP-Epac1 signaling in cell adhesion by ERM proteins. Mol Cell Biol 30: 5421-5431.
16. Grant S,. 2008. Cotargeting survival signaling pathways in cancer. J Clin Invest 118: 3003-3006.
17. Guertin DA, Sabatini DM,. 2007. New insights into mTOR signaling: mTORC2 and beyond. Cancer Cell 12: 9-22.
18. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen J-H, Mulholland DJ, Magnuson MA, Wu H, Sabatini DM,. 2009. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
19. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM,. 2006. Ablation in mice of the mTORC components Raptor, Rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-871. (Pubitemid 44804279)
20. Hanada M, Feng J, Hemmings BA,. 2004. Structure, regulation and function of PKB/AKT-A major therapeutic target. Biochim Biophys Acta 1697: 3-16. (Pubitemid 38326757)
21. Hanrahan J, Blenis J,. 2006. Rheb activation of mTOR and S6K1 signaling. Methods Enzymol 407: 542-555.
22. Hochbaum D, Barila G, Riberio-Neto F, Altschuler D,. 2011. Radixin assembles cAMP effectors Epac and PKA into a functional cAMP compartment: Role in cAMP-dependent cell proliferation. J Biol Chem 286: 859-866.
23. Houslay MD,. 2010. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35: 91-100.
24. Huston E, Lynch MJ, Mohamed A, Collins DM, Hill EV, MacLeod R, Krause E, Baillie GS, Housley MD,. 2008. EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proc Natl Acad Sci USA 105: 12791-12796.
25. Julian LA, Carriere A, Moreau J, Roux JP,. 2010. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30: 908-921.
26. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM,. 2004. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236. (Pubitemid 39006542)
27. Laplante M, Sabatini DM,. 2009. mTOR signaling at a glance. J Cell Sci 122: 3589-3594.
28. Liu C, Takahashi M, Li Y, Dillon TJ, Kaech S, Stork PJ,. 2010. The interaction of Epac1 and Ran promotes Rap1 activation at the nuclear envelope. Mol Cell Biol 30: 3956-3969.
29. Manning BD, Cantley LC,. 2007. AKT/PKB signaling: Navigating downstream. Cell 129: 1261-1274. (Pubitemid 46962095)
30. Martin DE, Hall MN,. 2005. The expanding TOR signaling network. Curr Opin Cell Biol 17: 158-166. (Pubitemid 40380939)
31. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J,. 2007. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of Rictor. Cancer Res 67: 11712-11720.
32. Mei FC, Qiao OM, Tsygankova LA, Meinkoth LA, Quilliam LA, Cheng X,. 2002. Differential signaling of cyclic AMP: Opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J Biol Chem 277: 11497-11504. (Pubitemid 34952919)
33. Misra UK, Pizzo SV,. 2005. Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling: Effects of silencing CREB gene expression on Akt activation. J Biol Chem 280: 38276-38289. (Pubitemid 43853725)
34. Misra UK, Pizzo SV,. 2009. Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. J Cell Biochem 108: 998-1011.
35. Misra UK, Akabani G, Pizzo SV,. 2002. The role of cAMP-dependent signaling in receptor-recognized forms of alpha 2-macroglobulin-induced cellular proliferation. J Biol Chem 277: 36509-36520.
36. Misra UK, Deedwania R, Pizzo SV,. 2006. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem 281: 13694-13707. (Pubitemid 43855285)
37. Misra UK, Kaczowka S, Pizzo SV,. 2008a. The cAMP-activated GTP exchange factor, Epac1 upregulates plasma membrane and nuclear Akt kinase activities in 8-CPT-2-O-Me-cAMP-stimulated macrophages: Gene silencing of the cAMP-activated GTP exchange Epac1 prevents 8-CPT-2-O-Me-cAMP activation of Akt activity in macrophages. Cell Signal 20: 1459-1470.
38. Misra UK, Kaczowka S, Pizzo SV,. 2008b. Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages. Cell Signal 20: 130-138. (Pubitemid 350138375)
39. Qiao J, Mei FC, Popov VL, Vergara LA, Cheng X,. 2002. Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP. J Biol Chem 277: 26581-26586. (Pubitemid 34967156)
40. Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Haung W, Largaespada DA, Marker PC,. 2009. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 69: 4388-4397.
41. Rampersad SN, Ovens JD, Huston E, Umana MB, Wilson LS, Netherton SJ, Lynch MJ, Baillie G, Houslay MD, Maurice DH,. 2010. Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability. J Biol Chem 285: 33614-33622.
42. Sabatini DM,. 2006. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6: 729-734. (Pubitemid 44286004)
43. Sehrawat S, Emandez T, Cullere X, Takahashi M, Oho Y, Komarova Y, Mayadas TN,. 2011. AKAP9 regulation of microtubule dynamics promotes Epac1-induced endothelial barrier properties. Blood 117: 708-718.
44. Sengupta S, Peterson TR, Sabatini DM,. 2010. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40: 310-322.
45. Sparks CA, Guertin DA,. 2009. Targeting mTOR: Prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29: 3733-3744.
46. Stork PJ,. 2003. Does Rap1 deserve a bad Rap? Trends Biochem Sci 28: 267-275. (Pubitemid 36588669)
47. Thediecke K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P, Arrieumerlou C, Hall MN,. 2007. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE 2: e1217.
48. Tzatsos A,. 2009. Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR. J Biol Chem 284: 22525-22535.
49. Wan X, Helman LJ,. 2005. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II- overexpressing rhabdomyosarcomas cells. Oncogene 22: 8205-8211. (Pubitemid 37487311)
50. Wilson LS, Baillie GS, Pritchard LM, Umana A, Terriu A, Zaccolo M, Houslay MD, Maurice DH,. 2011. A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J Biol Chem 286: 16285-16296.
51. Zhou H, Huang S,. 2010. mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr 20: 1-16.
52. Zoncu R, Efeyan A, Sabatini DM,. 2011. mTOR: From growth signal integration to cancer, diabetes, and aging. Nat Rev Mol Cell Biol 12: 21-35.